GeNeuro (FRA:GEM) Total Receivables: €0.00 Mil (As of Dec. 2023)


FRA:GEM GeNeuro SA FRA:GEM
8 GF Score
Price €0.03
View Full Analysis

What is GeNeuro Total Receivables?

GeNeuro FRA:GEM 8 Total Receivables is €0.00 Mil as of Dec. 2023. GuruFocus rates FRA:GEM with a GF Score™ of 8/100.

GeNeuro's Total Receivables for the quarter that ended in Dec. 2023 was €0.00 Mil.

GeNeuro Total Receivables Historical Data

* Premium members only.

The historical data trend for GeNeuro's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeNeuro Total Receivables Chart

GeNeuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.06 0.00 0.00 0.00

GeNeuro Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.15 0.00 0.00 0.00
FRA:GEM
8GF Score
GeNeuro SA FRA:GEM
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeNeuro Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.00 Mil mean?
GeNeuro (FRA:GEM) has a Total Receivables of €0.00 Mil as of Dec. 2023. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on GeNeuro and its competitors.
Is GeNeuro's Total Receivables too high?
GeNeuro's current Total Receivables is €0.00 Mil. Overall, GeNeuro has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does GeNeuro's Total Receivables compare to VRTX and REGN?
GeNeuro's Total Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on GeNeuro and its competitors. GeNeuro's current Total Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeNeuro stock overvalued right now?
GeNeuro (FRA:GEM) has a current Total Receivables of €0.00 Mil. The current Total Receivables is €0.00 Mil. GeNeuro's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For GeNeuro (FRA:GEM), the current Total Receivables is €0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GeNeuro Business Description

Address 3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
8GF Score

Get the complete analysis for FRA:GEM

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price